180 related articles for article (PubMed ID: 9756115)
1. Effective utilization of erythropoietin with intravenous iron therapy.
Bhandari S; Brownjohn A; Turney J
J Clin Pharm Ther; 1998 Feb; 23(1):73-8. PubMed ID: 9756115
[TBL] [Abstract][Full Text] [Related]
2. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
Park L; Uhthoff T; Tierney M; Nadler S
Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
[TBL] [Abstract][Full Text] [Related]
3. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy.
Bhandari S; Norfolk D; Brownjohn A; Turney J
Am J Kidney Dis; 1997 Dec; 30(6):814-21. PubMed ID: 9398126
[TBL] [Abstract][Full Text] [Related]
5. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
Sepandj F; Jindal K; West M; Hirsch D
Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients.
Low CL; Bailie GR; Eisele G
Ren Fail; 1997 Nov; 19(6):781-8. PubMed ID: 9415935
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
Driver PS
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
[TBL] [Abstract][Full Text] [Related]
8. Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.
Chen L; Jiang H; Gao W; Tu Y; Zhou Y; Li X; Zhu Z; Jiang Q; Zhan H; Yu J; Fu C; Gao Y
BMJ Open; 2016 Oct; 6(10):e012231. PubMed ID: 27855097
[TBL] [Abstract][Full Text] [Related]
9. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight iron dextran in the management of renal anaemia in patients on haemodialysis--the IDIRA Study.
Rath T; Florschütz K; Kalb K; Rothenpieler U; Schletter J; Seeger W; Zinn S
Nephron Clin Pract; 2010; 114(1):c81-8. PubMed ID: 19887827
[TBL] [Abstract][Full Text] [Related]
12. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
[TBL] [Abstract][Full Text] [Related]
13. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
14. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
15. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.
Takasawa K; Takaeda C; Wada T; Ueda N
Nutrients; 2018 Mar; 10(4):. PubMed ID: 29596361
[No Abstract] [Full Text] [Related]
16. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
19. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients.
Greenbaum LA; Pan CG; Caley C; Nelson T; Sheth KJ
Pediatr Nephrol; 2000 Sep; 14(10-11):908-11. PubMed ID: 10975297
[TBL] [Abstract][Full Text] [Related]
20. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
